Clinical Trial: Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07702955) titled 'Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors' on July 02.

Brief Summary: This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Advanced or Metastatic Solid Tumors

Intervention: DRUG: KGX105 injection

KGX105 is an inves...